Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 13/20 | 0.47 |
| ▸ | TRPC4 | Q9UBN4 | 2/20 | 0.45 |
| ▸ | TRPC5 | Q9UL62 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16028188 | 0.90 | P2RX3 (0.47) | SMN1; SMN2MAPK1L3MBTL1P2RX3TRPC4 | |
| SCHEMBL16028291 | 0.90 | P2RX3 (0.51) | SMN1; SMN2MAPK1L3MBTL1P2RX3TRPC4 | |
| SCHEMBL16028167 | 0.87 | P2RX3 (0.49) | SMN1; SMN2P2RX3TRPC4TRPC5KCNH2 | |
| SCHEMBL18833876 | 0.85 | P2RX3 (0.53) | SMN1; SMN2P2RX3TRPC4TRPC5KCNH2 | |
| SCHEMBL18834594 | 0.85 | P2RX3 (0.51) | SMN1; SMN2P2RX3TRPC4TRPC5KCNH2 | |
| SCHEMBL16028111 | 0.85 | P2RX3 (0.48) | SMN1; SMN2MAPK1L3MBTL1P2RX3TRPC4 | |
| SCHEMBL16076245 | 0.85 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPK1L3MBTL1TRPC4TRPC5 | |
| SCHEMBL16363504 | 0.85 | P2RX3 (0.46) | SMN1; SMN2P2RX3TRPC4TRPC5KCNH2 | |
| SCHEMBL16364269 | 0.85 | P2RX3 (0.49) | SMN1; SMN2P2RX3TRPC4TRPC5KCNH2 | |
| SCHEMBL16079033 | 0.85 | TRPC5 (0.62) | SMN1; SMN2P2RX3TRPC4TRPC5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2021-12-28 | — | — | US | disclosed |
| US-20190322667-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-10-24 | — | — | US | disclosed |
| US-10399982-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-9969736-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170305910-A1 | Substituted Xanthines and Methods of Use Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-10-26 | — | — | US | disclosed |
| US-20160237089-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | SMN1; SMN2 1307/4885MAPK1 3995/4885L3MBTL1 1412/4885 |
| US-20170305910-A1 | Substituted Xanthines and Methods of Use Thereof | TRPC5, TRPC7, TRPC4 | SMN1; SMN2 1307/4885MAPK1 3995/4885L3MBTL1 1412/4885 |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | SMN1; SMN2 1307/4885MAPK1 3995/4885L3MBTL1 1412/4885 |
| US-10399982-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | SMN1; SMN2 1307/4885MAPK1 3995/4885L3MBTL1 1412/4885 |
| US-20160237089-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | SMN1; SMN2 1307/4885MAPK1 3995/4885L3MBTL1 1412/4885 |
| US-11208409-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | SMN1; SMN2 1307/4885MAPK1 3995/4885L3MBTL1 1412/4885 |
| US-20190322667-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | SMN1; SMN2 1307/4885MAPK1 3995/4885L3MBTL1 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.